SAN DIEGO, April 1, 2019 – Primmune Therapeutics today announced that it will present preclinical data on a novel series of toll-like receptor 7 (TLR7) agonists engineered for systemic activation of innate immunity at the American Association for Cancer Research...
We use cookies to improve your experience on the Primmune website. By continuing to use our site, you agree to our use of cookies. Learn More
